Beatrix Children's Hospital
- Address
- Hanzeplein 1, 9713 GZ Groningen, The Netherlands
Beatrix Children's Hospital - Pediatric Metabolic and Renal Disorders Research Center
Beatrix Children's Hospital is a specialized pediatric research facility with notable expertise in rare metabolic disorders and complex renal diseases. The center is actively engaged in advancing therapeutic options for challenging conditions that significantly impact pediatric patient populations, focusing on both safety and efficacy outcomes in vulnerable patient groups.
- Rare kidney diseases including C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN)
- Metabolic disorders with emphasis on phenylketonuria (PKU) management and treatment optimization
- Long-term safety and efficacy evaluation of novel therapeutic agents in pediatric populations
The hospital demonstrates particular strength in phenylketonuria research, participating in multiple Phase 3 clinical trials investigating innovative treatments such as sepiapterin and comparative studies with established therapies. Additionally, the center contributes to groundbreaking research in complement-mediated renal disorders, evaluating novel therapeutics like pegcetacoplan for rare glomerulonephritis conditions. This comprehensive approach reflects the institution's commitment to addressing both metabolic and renal pathologies in children, with a focus on improving blood phenylalanine control in PKU patients and preserving kidney function in complement-mediated disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1PTC Therapeutics Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Beatrix Children's Hospital
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Crossover Study of Sepiapterin vs. Sapropterin in Phenylketonuria Patients Aged 2 Years and Older | PTC Therapeutics Inc. | Phase III | Not Recruiting | May 2024 | Jan 2025 |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (S)-2-Amino-6-(2-Hydroxypropanoyl)-7,8-Dihydropteridin-4(3H)-One | 2 | Unknown | 2022-09-28 | 2024-05-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.